Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2024-03-12 00:00:00 ET · period of report 2024-03-08 · accession 0001628280-24-010752 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-12 | 2024-03-08 | BLFS | Richardson Garrie | Chief Revenue Off | A - Grant | — | +12.5K | 117.8K | +12% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-08 | A | A | 12,516 | — | 117,843 | D | — | — | (F1) The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation. |